Data shows CAPR stock price gained 15% over the last quarter, outperforming small-cap biotech benchmarks, which rose by 9%. Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges. Read Our Latest Research Report on Capricor Therapeutics From an earnings perspective, CAPR stock price resilience points to investor anticipation of favorable trial results. Earnings multiples remain attractive compared to sector averages.
